重新评估导致噬菌体不适合用于治疗的因素。
Re-evaluating what makes a phage unsuitable for therapy.
作者信息
Cook Bradley W M, Hynes Alexander P
机构信息
Cytophage Technologies Inc., Oak Bluff, MB, Canada.
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
出版信息
NPJ Antimicrob Resist. 2025 May 29;3(1):45. doi: 10.1038/s44259-025-00117-z.
Abstract
One of the biggest challenges in phage therapy is selecting the 'right' phage. What constitutes a 'good' phage is unclear, but regulators are converging on exclusion criteria for 'bad' phages. Here, we examine three commonly applied criteria: the lack of virulence/antibiotic resistance, the inability to transduce, and being strictly lytic (virulent). We assess the risk posed, the tools for determining the criteria, and the potential impact of the criteria.
摘要
噬菌体疗法面临的最大挑战之一是选择“合适的”噬菌体。什么样的噬菌体才是“好”噬菌体尚不清楚，但监管机构正在就“坏”噬菌体的排除标准达成共识。在此，我们研究三个常用标准：无毒性/抗生素抗性、无转导能力以及严格裂解（烈性）。我们评估这些标准所带来的风险、判定标准的工具以及这些标准的潜在影响。
相似文献
1
Re-evaluating what makes a phage unsuitable for therapy.
NPJ Antimicrob Resist. 2025 May 29;3(1):45. doi: 10.1038/s44259-025-00117-z.
2
Preclinical characterization and in silico safety assessment of three virulent bacteriophages targeting carbapenem-resistant uropathogenic Escherichia coli.
Int Microbiol. 2024 Dec;27(6):1747-1763. doi: 10.1007/s10123-024-00508-8. Epub 2024 Mar 22.
3
The newly isolated lytic bacteriophages st104a and st104b are highly virulent against Salmonella enterica.
J Appl Microbiol. 2006 Jul;101(1):251-9. doi: 10.1111/j.1365-2672.2005.02792.x.
4
Odorant-specific patterns of sniffing during imagery distinguish 'bad' and 'good' olfactory imagers.
Chem Senses. 2005 Jul;30(6):521-9. doi: 10.1093/chemse/bji045. Epub 2005 Jul 19.
5
Transcriptomics-Driven Characterization of LUZ100, a T7-like Pseudomonas Phage with Temperate Features.
mSystems. 2023 Apr 27;8(2):e0118922. doi: 10.1128/msystems.01189-22. Epub 2023 Feb 16.
6
Two virulent Vibrio campbellii phages with potential for phage therapy in aquaculture.
BMC Microbiol. 2025 Feb 28;25(1):99. doi: 10.1186/s12866-025-03803-0.
7
Phage Therapy: A Different Approach to Fight Bacterial Infections.
Biologics. 2022 Oct 6;16:173-186. doi: 10.2147/BTT.S381237. eCollection 2022.
8
Genome Engineering of Virulent Lactococcal Phages Using CRISPR-Cas9.
ACS Synth Biol. 2017 Jul 21;6(7):1351-1358. doi: 10.1021/acssynbio.6b00388. Epub 2017 Mar 30.
9
Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in .
Front Cell Infect Microbiol. 2024 Jan 17;13:1280265. doi: 10.3389/fcimb.2023.1280265. eCollection 2023.
10
Defining early seizure outcomes in pediatric epilepsy: the good, the bad and the in-between.
Epilepsy Res. 2001 Jan;43(1):75-84. doi: 10.1016/s0920-1211(00)00184-4.
引用本文的文献
1
Phage Therapy: Combating Evolution of Bacterial Resistance to Phages.
Viruses. 2025 Aug 8;17(8):1094. doi: 10.3390/v17081094.
2
Temperate phages increase antibiotic effectiveness in a infection model.
mBio. 2025 Aug 18:e0162125. doi: 10.1128/mbio.01621-25.
3
Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections.
Gut Pathog. 2025 Aug 11;17(1):60. doi: 10.1186/s13099-025-00735-y.
4
Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.
Microb Biotechnol. 2025 Jul;18(7):e70193. doi: 10.1111/1751-7915.70193.
本文引用的文献
1
Prophages are infrequently associated with antibiotic resistance in clinical isolates.
mSphere. 2025 Mar 25;10(3):e0090424. doi: 10.1128/msphere.00904-24. Epub 2025 Feb 13.
2
Temperate phage-antibiotic synergy is widespread-extending to -but varies by phage, host strain, and antibiotic pairing.
mBio. 2025 Feb 5;16(2):e0255924. doi: 10.1128/mbio.02559-24. Epub 2024 Dec 20.
3
VFDB 2025: an integrated resource for exploring anti-virulence compounds.
Nucleic Acids Res. 2025 Jan 6;53(D1):D871-D877. doi: 10.1093/nar/gkae968.
4
Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.
Nat Microbiol. 2024 Jun;9(6):1434-1453. doi: 10.1038/s41564-024-01705-x. Epub 2024 Jun 4.
5
Temperate phage-antibiotic synergy across antibiotic classes reveals new mechanism for preventing lysogeny.
mBio. 2024 Jun 12;15(6):e0050424. doi: 10.1128/mbio.00504-24. Epub 2024 May 17.
6
Bacteriophages: Vectors of or weapons against the transmission of antibiotic resistance genes in hospital wastewater systems?
Water Res. 2024 Jan 1;248:120833. doi: 10.1016/j.watres.2023.120833. Epub 2023 Nov 7.
7
Analysis of viromes and microbiomes from pig fecal samples reveals that phages and prophages rarely carry antibiotic resistance genes.
ISME Commun. 2021 Oct 25;1(1):55. doi: 10.1038/s43705-021-00054-8.
8
Magistral Phage Preparations: Is This the Model for Everyone?
Clin Infect Dis. 2023 Nov 2;77(Suppl 5):S360-S369. doi: 10.1093/cid/ciad481.
9
Translating phage therapy into the clinic: Recent accomplishments but continuing challenges.
PLoS Biol. 2023 May 23;21(5):e3002119. doi: 10.1371/journal.pbio.3002119. eCollection 2023 May.
10
Synergistic Interactions among Complex-Targeting Phages Reveal a Novel Therapeutic Role for Lysogenization-Capable Phages.
Microbiol Spectr. 2023 Jun 15;11(3):e0443022. doi: 10.1128/spectrum.04430-22. Epub 2023 May 17.
Zotero 插件